Patient safety and product quality are its highest priorities Pfizer India has said, reacting to the Karnataka Food and Drug Administration (FDA) action regarding the circulation of counterfeit drugs. The Karnataka health regulator on Sunday said it has cancelled 16 drug…
Thiruvananthapuram, Oct 29: Remdesivir that expired in May 2023 was administered to patients, including those treated for Nipah infection, at hospitals in Kerala in subsequent years, Health Minister K. Muraleedharan told the Assembly on Thursday, ordering an investigation into whether the use of…
Updated - October 29, 2026 05:22 pm IST - Thiruvananthapuram A medical board will be constituted to investigate whether use of expired drug, Remdesivir, led to the deaths of Nipah patients. The board will also look into whether other patients who had been given the…
Acella Pharmaceuticals, LLC is voluntarily recalling a total of 13 lots of 30-mg, 60-mg and 90-mg NP Thyroid® (thyroid tablets, USP) to the consumer level. The products are being recalled because our testing has found these lots to be superpotent. The…
India has issued an urgent regulatory alert and mobilized drug inspectors nationwide after the World Health Organization (WHO) warned that a counterfeit batch of Defitelio (defibrotide), an intravenous drug used to treat severe hepatic veno-occlusive disease (VOD) following haematopoietic stem-cell…
AUBURN, Ala. — An Alabama company is recalling a popular thyroid pill after testing confirmed the product had the potential to be “superpotent.” In a company announcement posted to the U.S. Food and Drug Administration website on Monday, Vitruvias Therapeutics…
BETHLEHEM, Pa. — A Pennsylvania-based company on Wednesday issued a voluntary recall of a common intravenous fluid used by medical facilities to replace lost water and body salts. The company announcement states that the 1,000-millileter solution, which was distributed to facilities…
Apothecary Pharma, a drug compounder in Cary, North Carolina, is recalling 22 vials of compounded tirzepatide distributed nationwide because their sterility cannot be assured. The recall also includes one vial of an NAD+ injection, and no illnesses or injuries have been…
A retrospective study published in the Journal of the Endocrine Society evaluated 181 patients with intermediate-risk papillary thyroid cancer (PTC) treated between 2010 and 2022. Of these, 94... A retrospective study published in the Journal of the Endocrine Society evaluated 181 patients with intermediate-risk papillary…
Apothecary Pharma is recalling 22 vials of compounded tirzepatide and one NAD+ vial nationwide, citing a lack of assurance of sterility. A North Carolina outsourcing facility is pulling 22 vials of compounded tirzepatide injection from the market nationwide because it cannot assure…
Safety warnings, side effects, black-box labels and drug recalls, pharmacovigilance and substandard or counterfeit medicines.
An article joins this feed when it matches these terms. Each one is also a search of its own.